The SANGUINE Project represents a significant advancement in the early detection of hematological malignancies. This initiative aims to transform cancer care across Europe by introducing a cutting-edge blood test designed to identify blood cancers at their earliest stages. Early detection is crucial for improving patient outcomes and quality of life, and the SANGUINE Project is poised to become a standard tool in clinical practice. Biomarker Project Overview: The Foundation o

The fight against hematological malignancies demands innovative approaches and collaborative efforts. The SANGUINE project represents a significant leap forward in this battle by developing a cutting-edge blood test designed for early detection of blood cancers. My focus here is to explore FZMB's contribution to the SANGUINE project and how it supports the goal of transforming cancer care across Europe. Understanding FZMB's SANGUINE Project Role FZMB plays a pivotal role in

The SANGUINE project continues to make significant strides in the early detection of hematological malignancies through its innovative blood test technology. This initiative aims to transform cancer care across Europe by establishing a reliable, non-invasive diagnostic tool that can identify blood cancers at their earliest stages. In this post, I will share the latest updates on the project’s progress, technological advancements, and upcoming milestones. These developments ar

On May 2023, the Ebenstein lab and the SANGUINE project, in particular, were featured in one of the main news channels in Israel. The...

FZMB released PR in several local channels, presenting the SANGUINE project. Also here, here, and here.

The SANGUINE clinical trial is listed in NIH, at ClinicalTrials.gov, with identifier: NCT05735704.